Request for Trading Halt
Release Date: 29/01/2013 12:00am
Pharmaxis Ltd requests an immediate trading halt of its securities pending the completion, and announcement of the outcome, of the review of Bronchitol® for the treatment of cystic fibrosis by the Pulmonary-Allergy Drug Advisory Committee or “PADAC”, an independent expert advisory panel to the U.S. Food and Drug Administration.
The PADAC review meeting is being held on Wednesday 30 January 2013 (U.S. time). The briefing information for the PADAC meeting has been released publicly overnight on the FDA website in accordance with the FDA’s standard process and the Company is not in a position to comment on the briefing materials until the meeting process has been concluded. The Company’s announcement in relation to the outcome of the review process is expected to be made on the morning of Thursday, 31 January 2013.
Categories: ASX Announcements